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Summary
The Task Force on Community Preventive Services conducted systematic reviews to evaluate the effectiveness of interven-
tions to improve targeted vaccination coverage (i.e., coverage with vaccines recommended for some but not all persons in an
age range on the basis of risk for exposure or disease) among adults aged <65 years at high risk when implemented alone
(single-component interventions) and in combination with other interventions (multicomponent interventions). A 1999
report by the Task Force examined the effectiveness of interventions to increase coverage with universally recommended
vaccinations (i.e., vaccines recommended for all persons in particular age groups). Three targeted vaccinations recom-
mended for populations at risk are addressed in this review: influenza, pneumococcal polysaccharide, and hepatitis B. The
Task Force identified evidence that certain combinations of interventions have improved vaccination coverage. To increase
targeted vaccination coverage, the Task Force recommends a combination of interventions that include selected interven-
tions from two or three categories of interventions (i.e., increasing community demand for vaccinations, enhancing access
to vaccination services, and provider- or system-based interventions). The Task Force also recommends provider reminders,
when implemented alone, to improve targeted vaccination coverage. This report provides additional information about
population-based interventions to improve the coverage of influenza, pneumococcal polysaccharide, and hepatitis B vac-
cines among populations at risk, briefly describes how the reviews were conducted, and provides information that can help
in applying the interventions locally.
Background
Influenza, pneumococcal infections, and hepatitis B are
vaccine-preventable diseases that cause substantial illness and
premature death in the United States (1–3). Rates of morbid-
ity and mortality are higher among adults with certain medi-
cal conditions, occupational exposures, or risk behaviors
(2,4,5). Efforts to reduce the burden of these diseases depend
on increasing vaccination coverage in the population, espe-
cially among adults at high risk. This report provides recom-
mendations from the Task Force on Community Preventive
Services (Task Force) for use of population-based interven-
tions to improve the coverage of influenza, pneumococcal
polysaccharide, and hepatitis B vaccines among adults aged
<65 years at high risk, with occupational exposure, risky be-
haviors, or medical conditions (targeted vaccinations). Previ-
ously, the Task Force evaluated the effectiveness of interventions
to increase coverage with universally recommended vaccina-
tions (i.e., those recommended for all persons in particular
age groups) (6–8).
Influenza
Influenza causes an estimated 114,000 excess hospitaliza-
tions (5) and 36,000 deaths (3) annually in the United States.
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Morbidity and mortality rates are high among adults aged >65
years and among younger persons who have medical condi-
tions that place them at risk for complications from the dis-
ease (e.g., diabetes or lung or heart disease). Influenza
vaccination is effective in preventing hospitalization and death
among persons with high-risk medical conditions (9). Influ-
enza coverage rates among adults aged <65 years with one or
more risk conditions ranged from 20.4% (aged 18–49 years)
to 37.7% (aged 50–64 years) in 1995 (10) and remained low
(32%) among adults aged 18–64 years in 2002 (National
Health Interview Survey [NHIS], unpublished data, 2002).
Pneumococcal Disease
In the United States, approximately 3,500 persons aged <65
years die every year as a result of pneumococcal disease (2).
Pneumococcal infections cause an estimated 3,000 cases of
meningitis, 50,000 cases of bacteremia, and 500,000 cases of
pneumonia annually (11). Efficacy rates for the 23-valent vac-
cine in studies of immunocompetent adults ranged from 65%
to 75% in the prevention of pneumococcal bacteremia and
meningitis (12,13). Despite the efficacy of the vaccine, vacci-
nation coverage remains low for adults aged 18–64 years with
risk conditions. Coverage rates for pneumococcal polysaccha-
ride vaccine among adults aged <65 years with one or more
risk conditions ranged from 11.8% (aged 18–49 years) to
20.1% (aged 50–64 years) in 1995 (10) and remained low
(19.1%) among persons aged 18–64 years in 2002 (NHIS,
unpublished data, 2002).
Hepatitis B
An estimated 1.0–1.3 million persons in the United States
are chronically infected with hepatitis B virus (HBV) (14), of
whom approximately 5,000 die of HBV-related cirrhosis or
liver cancer each year (15–17). Risk conditions for hepatitis B
include occupational exposures and risk behaviors (e.g.,
injection-drug use and multiple sex partners). Although re-
ported cases of HBV declined 76% during 1987–1998 (18),
the annual number of new infections remained substantial with
78,000 cases estimated in 2001 (19). Despite the availability
of an effective vaccine, vaccination coverage rates remain low
in the majority of targeted populations. In one study, 9% of
men who have sex with men (MSM) had both a history and
serologic evidence of hepatitis B vaccination in 1998 (20).
Among injection-drug users attending a sexually transmitted
disease clinic in San Diego during 1998–2001, vaccination
coverage for hepatitis B was 6% (21). Among occupationally
exposed workers, vaccination coverage is approximately 75%,
and with increasing vaccination coverage, the estimated num-
ber of HBV infections among health-care workers in the United
States has decreased from >10,000 in 1983 to approximately
400 in 2002 (22,23).
Targeted vaccination coverage rates for influenza, pneumo-
coccal polysaccharide, and hepatitis B vaccines in adult popu-
lations at high risk remain low and below the Healthy People
2010 objectives (24). These objectives include increasing both
influenza and pneumococcal vaccination coverage among
adults at high risk to 60% and increasing hepatitis B vaccine
coverage among high-risk groups, including hemodialysis pa-
tients (to 90%), MSM (to 60%), and occupationally exposed
workers (to 98%).
Introduction
The independent, nonfederal Task Force on Community
Preventive Services leads work on the Guide to Community
Preventive Services (the Community Guide), a resource that in-
cludes multiple systematic reviews, each focusing on a preven-
tive health topic. The Community Guide is being developed
with the support of the U.S. Department of Health and Hu-
man Services (DHHS) in collaboration with public and pri-
vate partners. Although CDC provides staff support to the
Task Force for development of the Community Guide, the rec-
ommendations presented in this report were developed by the
Task Force and are not necessarily the recommendations of
DHHS, CDC, or other participating groups.
This report is one in a series of topics included in the Com-
munity Guide. It provides an overview of the process used by
the Task Force to select and review evidence and summarize its
recommendations about interventions to improve targeted
vaccination coverage among adults at high risk. A full report
on the recommendations, additional evidence (i.e., discussions
of applicability; additional benefits; potential harms; existing
barriers to implementation; and costs, cost-benefit, and cost-
effectiveness [when available] of recommended interventions),
and remaining research questions will be published in the
American Journal of Preventive Medicine in 2005.
Community Guide topics are prepared and released as each is
completed. The findings from systematic reviews on improv-
ing coverage with universally recommended vaccines, tobacco-
use prevention and reduction, reducing motor-vehicle occupant
injury, increasing physical activity, diabetes management, oral
health, skin cancer prevention, violence prevention, and the
effects of the social environment on health have already been
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published. A compilation of systematic reviews has been pub-
lished in book form (The Guide to Community Preventive Ser-
vices. What Works to Promote Health?). Additional information
about the Task Force and the Community Guide and a list of
published articles are available at http://www.
thecommunityguide.org.
Methods
The methods used by the Community Guide for conducting
systematic reviews and linking evidence to recommendations
have been described elsewhere (25). For each Community Guide
topic, a multidisciplinary team (the systematic review develop-
ment team composed of Community Guide researchers and
methodologists, Task Force members, and other subject matter
specialists)* conducts a review consisting of the following steps:
• developing an approach to organizing, grouping, and se-
lecting the interventions;
• systematically searching for and retrieving evidence;
• assessing the quality and summarizing the strength of the
body of evidence on effectiveness;
• translating the body of evidence on effectiveness into
conclusions;
• assessing evidence about economic efficiency, applicability,
other positive and negative effects, and barriers to imple-
mentation (if the effectiveness of the intervention has been
established); and
• identifying and summarizing research gaps.
The same conceptual approach and model (logic framework)
used in the initial systematic reviews of vaccine-preventable
diseases for the Guide to Community Preventive Services in 2000
(6) was adopted for this review. As in the initial review, the
systematic review development team focused on the following
three categories of interventions:
• Interventions to increase community and client demand
for vaccines and vaccination services. These efforts pro-
vide or disseminate information, advice, or both to
clients to increase and improve their efforts to seek
appropriate vaccination.
• Interventions to enhance access to vaccination services.
These efforts reduce barriers clients might encounter in
attempting to receive vaccinations.
• Provider- or system-based interventions. These interven-
tions provide information or deliver timely reminders or
periodic feedback to health-care providers with the intent
of increasing provider counseling about, and administra-
tion of, appropriate vaccinations to clients.
The Task Force previously reviewed the evidence on inter-
ventions to improve coverage of universally recommended vac-
cinations (i.e., vaccines recommended for all persons in
particular age groups) in children, adolescents, and adults
(6–8). This review is an expansion of the original Community
Guide review and evaluates the effectiveness of interventions
to increase targeted vaccine coverage among populations at
high risk. Although barriers to vaccination are similar for uni-
versally recommended and targeted vaccinations, the popula-
tions are different. This review focused on interventions
conducted among adults aged <65 years with medical condi-
tions such as diabetes, human immunodeficiency virus, heart
disease, and lung disease; health-care workers at high risk for
occupational exposure; and persons with high-risk behaviors
for HBV infection (e.g., injection-drug use or multiple sex
partners). Because these groups might be harder to reach than
those for whom universally recommended vaccinations are
appropriate, the Task Force conducted reviews specifically ad-
dressing these populations at risk.
The team reviewed the same interventions selected for the
initial review of strategies to increase coverage for universally
recommended vaccines, adding new studies published during
1997–2001. Studies were eligible for inclusion in the reviews
of effectiveness if they 1) were primary investigations of inter-
ventions selected for evaluation rather than, for example, guide-
lines or reviews; 2) were published in English during January
1980–August 2001; 3) compared outcomes among groups of
persons exposed to the intervention with outcomes among
groups of persons not exposed or less exposed to the interven-
tion (i.e., the study design included a concurrent or before-
and-after comparison); 4) were conducted in established market
* The systematic review development team directs the review, in conjunction
with a group of consultants. For these reviews, the members of the systematic
review development team were David P. Hopkins, MD, Peter A. Briss, MD,
Division of Prevention Research and Analytic Methods, Epidemiology
Program Office; Serigne M. Ndiaye, PhD, Lance E. Rodewald, MD, Abigail
M. Shefer, MD, Bayo Willis, MPH, National Immunization Program, CDC,
Atlanta, Georgia; Alan R. Hinman, MD, Task Force for Child Survival and
Development, Atlanta, Georgia. Consultants were Bob Gunn, MD, National
Center for HIV, STD and TB Prevention, CDC, Atlanta, Georgia; Joseph
Chin, MD, Center for Medicare Services, Baltimore, Maryland; Lloyd Novick,
MD, Onondaga County Health Department, Syracuse, New York; Rose Marie
Matulionis, MSPH, Association of State and Territorial Directors of Health
Promotion and Public Health Education, Washington, DC; Susan Lett, MD,
Massachusetts Department of Health, Boston; Tracy Lieu, MD, Harvard
University, Cambridge, Massachusetts; Theresa W. Gyorkos, PhD, Montreal
General Hospital and McGill University, Montreal, Quebec, Canada; Tom
Saari, MD, University of Wisconsin, Madison; William Schaffner II, MD,
Vanderbilt University, Nashville, Tennessee; Peter Szilagyi, MD, University
of Rochester, New York.
4 MMWR April 1, 2005
economies;† 5) measured differences or changes in vaccina-
tion coverage; 6) were studies of influenza, pneumococcal
polysaccharide, or hepatitis B vaccines; and 7) were studies of
populations that either focused on or included persons aged
<65 years and at high risk for infection, morbidity, or mortality.
The team used multiple strategies to identify studies of in-
terventions, starting with a search of 12 computerized data-
bases (MEDLINE®, Embase, Psychlit, Sociological Abstracts,
CabHealth, HealthStar, AIDSline, Occupational Safety and
Health Database, Educational Resource Information Center
[ERIC], PsycINFO®, Dissertation Abstracts, and Conference
Papers Index).§ Team members also reviewed reference lists of
published studies and consulted with specialists in the field to
identify relevant studies. Each study was evaluated by two in-
dependent reviewers using a standardized abstraction form and
was assessed for suitability of the study design and threats to
validity (25,26). Studies were characterized as having good,
fair, or limited execution on the basis of the number of threats
to validity (25). Studies with greatest or moderate design suit-
ability and a good or fair quality of execution were considered
qualifying studies and became part of the body of evidence.
Results for each outcome of interest were obtained from each
study that met the minimum quality criteria. For this review,
assessment of the effectiveness of an intervention was prima-
rily based on the reported measurements of changes in cover-
age rates for influenza, pneumococcal polysaccharide, or
hepatitis B vaccination. In studies with concurrent compari-
son groups, the overall change in vaccination coverage was
calculated by using the difference in vaccine coverage change
observed in the intervention and comparison groups. In
studies without a concurrent comparison group (e.g., time se-
ries evaluations), the absolute percentage change was calcu-
lated from measurements of vaccination coverage in the study
population pre- and postintervention.¶ The median was used
to summarize a typical measure of effect across the body of
evidence for each outcome of interest; both the median and
the range are reported.
The strength of the body of evidence of effectiveness was
characterized as strong, sufficient, or insufficient on the basis
of the number of available studies, the suitability of study de-
signs for evaluating effectiveness, the quality of execution of
the studies as defined by the Community Guide (25), the con-
sistency of the results, and a determination of median effect size
sufficient for the purpose of public health benefit.
The Task Force uses systematic reviews to evaluate the evi-
dence of intervention effectiveness and makes recommenda-
tions on the basis of the findings of the reviews (25). The
strength of each recommendation is based on the evidence of
effectiveness (i.e., an intervention is recommended on the ba-
sis of either strong or sufficient evidence of effectiveness) (25).
Other types of evidence can also affect a recommendation.
For example, harms resulting from an intervention that out-
weigh benefits might lead to a recommendation that the
intervention not be used even if it is effective in improving
certain outcomes.
A finding of insufficient evidence to determine effectiveness
means that the team was not able to determine whether or not
the intervention is effective. This finding is important for iden-
tifying areas of uncertainty and continuing research needs. In
contrast, sufficient or strong evidence of ineffectiveness would
lead to a recommendation against use of the intervention.
In its earlier review of universally recommended vaccines,
the Task Force summarized the evidence on effectiveness of
interventions implemented in combination within defined
† Established Market Economies, as defined by the World Bank, are Andorra,
Australia, Austria, Belgium, Bermuda, Canada, Channel Islands, Denmark,
Faeroe Islands, Finland, France, Germany, Gibraltar, Greece, Greenland, Holy
See, Iceland, Ireland, Isle of Man, Italy, Japan, Liechtenstein, Luxembourg,
Monaco, The Netherlands, New Zealand, Norway, Portugal, San Marino,
Spain, St. Pierre and Miquelon, Sweden, Switzerland, the United Kingdom,
and the United States.
§ These databases can be accessed as follows: MEDLINE: http://
www.ncbi.nlm.nih.gov/PubMed; Embase: http://www.ovid.com/site/catalog/
DataBase/903. j sp;  Psychl i t :  http://www.ovid.com/si te/cata log/
Catalog_DataBase.jsp; Sociological Abstracts, http://dialogclassic.com
(requires id/password account), http://www.csa.com/detailsV5/socioabs.html;
CabHealth: http://www.datastarweb.com; HealthStar: http://www.
nlm.nih.gov/services/igm.html; AIDSline: http://www.ovid.com/site/catalog/
Catalog_DataBase.jsp; Occupational Safety and Health Database: http://
www.cdc.gov/niosh/database.html; Educational Resource Information Center
(ERIC): http://www.askeric.org/Eric/; PsycINFO: http://www.dialogic.com
(requires ID/password account), http://www.apa.org/psycinfo/products/
psycinfo.html; Dissertation Abstracts: http://www.ovid.com/site/catalog/
Catalog_DataBase.jsp; Conference Papers Index: http://www.csa.com/csa/
factsheets/cpilong.shtml (requires subscription).
¶ In studies with concurrent comparison groups, the overall change in
vaccination coverage was calculated by using the difference between the
changes in vaccination coverage observed in the intervention and comparison
groups. In time-series studies, the absolute percentage point change over time
was derived.
In these calculations, Ipost = last reported coverage in the intervention group
after the intervention; Ipre = reported coverage in the intervention group
immediately before the intervention; Cpost = last reported coverage in the
comparison group after the intervention; and Cpre = reported coverage in
the comparison group immediately before the intervention.
• For studies with before-and-after measurements and concurrent compari-
son groups, where baseline = Ipre:
(Ipost – Ipre) – (Cpost – Cpre)
• For studies with post-only coverage measurements and concurrent com-
parison groups, where baseline = Cpost:
Ipost – Cpost
• For studies with before-and-after measurements but no concurrent com-
parison, where baseline = Ipre:
Ipost – Ipre
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multicomponent categories (e.g., multicomponent interven-
tions that include patient or provider education) (26). The
multicomponent body of evidence summarized in the current
reviews consisted predominantly of studies evaluating unique,
overlapping combinations of interventions. A multicompo-
nent framework was initially developed in these reviews, but
the Task Force later determined that a simplified, qualitative,
and conceptual categorization of interventions within a “menu”
format provides a more accurate and useful assessment of the
evidence. Studies with similar but not identical combinations
of interventions within or across categories were evaluated to-
gether as a body of evidence. Effectiveness was determined for
each possible combination of categories. After effective cat-
egory combinations were identified, specific interventions with
sufficient evidence on effectiveness as part of a multicompo-
nent effort were included as category options in the menu (re-
sults of this review are presented elsewhere) (27). This approach
introduces an additional qualitative method for Task Force
recommendations while acknowledging the work of previous
investigators who developed and implemented intervention
combinations on the basis of a conceptual understanding of
vaccination demand and delivery (28).
Results
The team identified 2,461 titles and abstracts, of which 60
met the inclusion criteria. Of these, 25 were excluded on the
basis of limitations in their design or execution and were not
considered further. The remaining 35 studies were considered
qualifying studies and form the basis for the Task Force evalu-
ations reported here. Reviews identified strong evidence of ef-
fectiveness in increasing targeted vaccine coverage for provider
reminder systems when implemented alone. The evidence was
insufficient to determine the effectiveness of all other inter-
ventions when implemented alone (single-component inter-
ventions). All 11 single-component interventions are described
here (Table 1), and a more detailed report will be published
elsewhere (27).
The findings of the systematic review of interventions to
increase targeted vaccine coverage when implemented in com-
bination (multicomponent) are based on 23 studies (29–51).
Overall, the 23 qualifying studies provided 26 study arms evalu-
ating 22 different combinations of interventions. Seven study
arms in seven studies evaluated one of three specific interven-
tion combinations: two studies evaluated a combination of
client reminders and provider reminders; two used a combi-
nation of client education, client reminders, and expanded ac-
cess in a health-care setting; and three used a combination of
client education, client reminders, expanded access, and re-
duced client out-of-pocket costs. The remaining 19 study arms
evaluated unique combinations of interventions.
Because the majority of studies evaluated unique combina-
tions of interventions, the team examined the evidence of ef-
fectiveness of combinations of interventions within and across
three categories of vaccination delivery (i.e., enhancing access
to vaccination services, provider- or system-based interven-
tions, and increasing client or community demand) (Table 2).
On the basis of strong evidence of effectiveness, the Task
Force recommends the combination of one or more interven-
tions to enhance access to vaccination services (expanded
access in health-care settings or reduced client out-of-pocket
costs) with at least one provider- or system-based intervention
(standing orders, provider reminder systems, or provider as-
sessment and feedback), and/or at least one intervention to
increase client or community demand for vaccination (client
reminders or client education). The menu format of this rec-
ommendation is presented (Table 3). Evidence was insuffi-
cient to determine the effectiveness of other combinations
across or within categories.
Although incremental improvements in vaccine coverage
could not be attributed to the specific components, combined
activities improved vaccination coverage. This could reflect any
of the following:
• The combined activities reinforce one another (e.g., edu-
cation alone might not be enough to increase acceptance
of vaccinations, but could make clients more receptive to
other components).
• Multicomponent interventions are delivered more inten-
sively than single-component interventions.
• More studies have been conducted of multicomponent
interventions than single-component.
• Multicomponent interventions might increase the likeli-
hood of a client’s exposure to at least one component.
The results of this review should be applicable in the
majority of client and provider populations and the majority
of settings where improvements in coverage are needed. Inter-
ventions were evaluated among outpatients, inpatients, health-
care workers, nurses, and faculty physicians. Evaluated
health-care settings included academic programs, outpatient
clinics, hospitals, and long-term care facilities. No additional
positive or negative effects specific to the combination of in-
terventions were identified in this review, although positive or
negative effects of single-component interventions might re-
main relevant (6). Economic evaluations of the effects of these
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TABLE 1. Recommendations from the Task Force on Community Preventive Services on population-based interventions, when
implemented alone, to improve targeted vaccination coverage among adults aged <65 years at high risk.
Interventions
(number of qualifying studies) Task Force recommendation Intervention description Key findings
Interventions to enhance access to vaccination services
Expanding access in health-care
settings (n = 0)
Insufficient evidence to determine
effectiveness*
Expanding access increases the
availability of vaccines in medical or
public health clinic settings in which
vaccinations are offered by 1)
reducing the distance between the
setting and the population; 2)
increasing or changing hours during
which vaccination services are
provided; 3) delivering vaccinations
in clinical settings in which they were
previously not provided (e.g.,
emergency departments, inpatient
units, or subspecialty clinics); or 4)
reducing administrative barriers to
obtaining vaccination services within
clinics (e.g., developing a “drop-in”
clinic or an “express lane” vaccina-
tion service).
Insufficient evidence to determine
effectiveness in improving
influenza, pneumococcal polysac-
charide, or hepatitis B vaccination
coverage among adults at high risk
because no studies were
identified.
Reducing out-of-pocket costs (n = 0) Insufficient evidence to determine
effectiveness*
Health-care system efforts to
reduce the out-of-pocket costs to
the client for vaccination services
include paying for the vaccines or
administration, providing insurance
coverage, or reducing co-
payments for vaccinations at the
point of service.
Insufficient evidence to determine
effectiveness in improving
influenza, pneumococcal polysac-
charide, or hepatitis B vaccination
coverage among adults at high risk
because no qualifying studies were
identified.
Provider- or system-based interventions
Provider reminders (n = 7) Recommended Provider reminder interventions are
used to inform those who adminis-
ter vaccinations that individual
clients are due for specific
vaccinations.  Techniques by which
reminders are delivered vary, from
the use of notations in clients’
charts, to attached chart prompt or
stickers, to standardized checklists
generated by the clinical staff or
developed from computer
databases and registries. Remind-
ers can be directed to primary
health-care providers or to one or
more members of the clinic staff.
Provider reminders are recom-
mended by the Task Force on the
basis of strong evidence of
effectiveness in improving targeted
vaccination coverage. The body of
evidence identified in the review
included two studies of provider
reminders focused on influenza
vaccination, one study focused on
pneumococcal vaccine, and four
studies of both influenza and
pneumococcal vaccination. The
median increase in vaccination
coverage was 22 percentage
points (range: 8–72).
Assessment and feedback for
vaccination providers (n = 1)




evaluating the performance of
providers in delivering one or more
vaccinations to client populations
and giving this information to
providers. This study evaluated the
effect of annual chart reviews and
feedback on coverage of influenza
and pneumococcal polysaccharide
vaccines.




coverage among adults at high
risk. Although this study docu-
mented a 32 percentage point
improvement in coverage for
influenza vaccine and an 18
percentage point improvement for
pneumococcal polysaccharide
vaccine, these findings alone are
not sufficient to determine whether
the intervention is effective.
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TABLE 1. (Continued) Recommendations from the Task Force on Community Preventive Services on population-based
interventions, when implemented alone, to improve targeted vaccination coverage among adults aged <65 years at high risk.
Interventions
(number of qualifying studies) Task Force recommendation Intervention description Key findings
Provider- or system-based interventions
Provider education (n = 0) Insufficient evidence to determine
effectiveness*
Provider education involves giving
information about vaccinations to
providers to increase their knowledge
or change their attitudes. Techniques
by which information is delivered can
include written materials, videos,
lectures, continuing medical
education programs, or computer-
ized software.
Insufficient evidence to determine
effectiveness in improving
influenza, pneumococcal polysac-
charide, or hepatitis B vaccination
coverage among adults at high risk
because no studies were identified
in the review.
Standing orders (n = 0) Insufficient evidence to determine
effectiveness*
Standing orders involve interventions
in which nonphysician personnel
(e.g., nurses or pharmacists)
prescribe or deliver vaccinations to
client populations by protocol without
direct physician involvement at the
time of interaction.
Insufficient evidence to determine
effectiveness in improving
influenza, pneumococcal polysac-
charide, or hepatitis B vaccination
coverage among adults at high risk
because no studies were identified
in the review.
Interventions to increase community and client demand
Client reminders (n = 1) Insufficient evidence to determine
effectiveness*
Client reminder interventions
involve reminding members of a
target population that vaccinations
are due. Reminders differ in
content and are delivered by
various methods (e.g., telephone,
letter, or postcard).
In the one study, clients received a
postcard with a message signed
by their providers, reminding them
to get a “flu shot”.
Insufficient evidence to determine
effectiveness in improving
influenza vaccination coverage
among adults at high risk because
only one study was available.




to clients served in a specific
medical or public health clinic
setting. In one study, information
or information plus individualized
decision analysis were provided to
clients to increase coverage with
hepatitis B vaccine. In the other
study, clients received an
educational handout to increase
coverage with pneumococcal
polysaccharide vaccine.
Insufficient evidence to determine
effectiveness in improving
influenza, pneumococcal polysac-
charide, or hepatitis B vaccination
coverage among adults at high risk
because of the limited number of
studies.




to the majority of or all of a target
population in a geographic area.
Educational messages can be
delivered by various methods (e.g.,
radio, newspapers, television, or
posters).
Insufficient evidence to determine
effectiveness in improving
influenza, pneumococcal polysac-
charide, or hepatitis B vaccination
coverage among adults at high risk
because no qualifying studies were
identified.
Client or family incentives (n = 1) Insufficient evidence to determine
effectiveness*
Client or family incentives involve
motivating clients (or patients) with
rewards (e.g., money or discount
coupons at retail stores) or the
threat of penalties (e.g., being
excluded from participating in a
program). The study in the review
evaluated the effectiveness of a
$10 incentive on increasing receipt
of hepatitis B vaccination among
injection-drug users.
The study documented a 35
percentage point increase in
vaccine coverage. However, this
study did not provide sufficient
evidence to determine the
effectiveness of the intervention.
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TABLE 3. Menu format of intervention combinations recommended by the Task Force on Community Preventive Services to
increase targeted vaccinations
One or both of these interventions to enhance access to vaccination services: — Expanded access in health-care settings
— Reducing client out-of-pocket costs
plus
One or more of these provider- or system-based interventions: — Standing orders
— Provider reminder systems
— Provider assessment and feedback
and/or
One or both of these interventions to increase client demand — Client reminder systems
 for vaccination services: — Client education
TABLE 1. (Continued) Recommendations from the Task Force on Community Preventive Services on population-based
interventions, when implemented alone, to improve targeted vaccination coverage among adults aged <65 years at high risk.
Interventions
(number of qualifying studies) Task Force recommendation Intervention description Key findings
Interventions to increase community and client demand
Vaccination requirements (n = 0) Insufficient evidence to determine
effectiveness*
Vaccination requirements include
laws or policies requiring vaccina-
tion or other documentation of
immunity as a condition of
attendance (e.g., for child care,
school, or college), residence (e.g.,
residential or long-term care
facilities), or employment (e.g.,
health-care worker).
Insufficient evidence to determine
effectiveness in improving
influenza, pneumococcal polysac-
charide, or hepatitis B vaccination
coverage among adults at high risk
because no qualifying studies were
found.
* Insufficient evidence to determine effectiveness means that the Task Force could not determine whether or not the intervention works. A determination of
insufficient evidence assists in identifying areas of uncertainty about an intervention’s effectiveness and specific continuing research needs.
TABLE 2. Evidence of effectiveness of intervention combinations in increasing coverage of targeted vaccinations in populations
at high risk
Combinations across categories of interventions evaluated in the studies qualifying for review
Interventions to enhance Provider- or system- Interventions to increase Results from studies
access to vaccination services based interventions client or community demand qualifying for review
Intervention combinations with sufficient evidence of effectiveness
Intervention combinations with insufficient evidence to determine effectiveness
* One qualifying study evaluated the combination of provider education and provider assessment and feedback.
† One qualifying study evaluated the combination of client education and client reminders.
X X X Four studies: median change:
22.8 percentage points
(range: -5.9–67.0)
X X Nine studies: median change:
14 percentage points
(range: 3.1–46.0)




X X Five studies: median change:
3.7 percentage points
(range: -2.0–28.9)
X No studies identified
X* One study: 11 percentage points
One study: 13.6 percentage
points
X†
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protects the health-care worker who is vaccinated, whereas in-
fluenza vaccine also protects those patients with whom the
health-care worker comes in contact), the Task Force recom-
mendation reflects confidence that effective efforts to increase
influenza vaccine coverage among health-care workers can also
be applicable to efforts to vaccinate health-care workers against
hepatitis B.
Community-based options for interventions to increase vac-
cination coverage of persons at high risk for HBV are one im-
portant area in which substantial gaps remain in the evidence
on effectiveness. Substantial differences in the hepatitis B vac-
cination schedule (a series of three injections), the target popu-
lations (persons with high-risk behaviors such as injection-drug
use), and the settings for intervention (not primary health-
care settings) are unlikely to be overcome through the direct
application of health-care system strategies demonstrated to
be effective in other targeted vaccination efforts (28). Effec-
tive and recommended health-care–based interventions might
not be applicable or might require considerable modification
to fit community-based programs to increase HBV coverage
in populations at high risk. Practitioners should ensure that
interventions are selected or modified to address locally relevant
barriers to vaccination. Researchers should consider more stud-
ies of this problem.
In 2000, the Advisory Committee on Immunization Prac-
tices updated their universal recommendations for annual in-
fluenza vaccination to include adults aged 50–64 years (54).
Program planners dedicated to increasing influenza vaccina-
tion coverage within this population should consider recom-
mendations from either or both Task Force reviews applicable.
For initial efforts, the recommendations in the original, uni-
versal review provide effective and flexible intervention op-
tions (6,8). For enhancing initial program efforts, the
information on intervention combinations recommended in
this targeted review might be helpful.
Certain studies included in these reviews evaluated inter-
ventions or combinations of interventions implemented to
increase vaccine coverage among all adult patients within a
health-care system (including both patients with universal and
high-risk indications). To match effective interventions to
local needs, program planning should include an assessment
of existing disparities, if any, in vaccine coverage among adult
patients with universal and targeted indications.
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